TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: More importantly, we demonstrated that 22q loss was significantly associated with aggressive clinical features and an independent predictor of worse outcomes for patients with TFE3-tRCC.